Hager Biosciences LLC has identified orexin receptor and/or κ-opioid receptor dual antagonists reported to be useful for the treatment of cancer, psychiatric, neurological and cardiovascular disorders.

Bristol Myers Squibb Co. has patented Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of cancer.

The Scripps Research Institute has disclosed peptides and their drug conjugates acting as dual gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, metabolic dysfunction-associated steatotic liver disease and obesity.

Nanjing Nuoyuan Medical Devices Co. Ltd. has discovered drug conjugates comprising a fluorescent moiety targeting hepatocyte growth factor receptors (HGFR; MET) covalently linked to crizotinib through a linker. They are reported to be useful for diagnosis of liver and colon cancer.

Neushen Therapeutics Inc. has patented NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Huntington’s disease.

Asieris Pharmaceuticals Co. Ltd. has identified compounds acting as inhibitors of CDK1/cyclin A2, CDK2/cyclin E1, CDK4/cyclin D1 and CDK6/cyclin D1 reported to be useful for the treatment of breast and ovary cancer.

Perseus Proteomics Inc. and Ube Corp. have disclosed antibody-drug conjugates (ADCs) comprising antibodies T004b-PGAP-1 targeting human P-cadherin (CDH3) targeting covalently linked to cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Weatherwax Biotechnologies Corp. has prepared and tested cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

China Pharmaceutical University has patented non-ubiquitin proteolysis targeting chimera (NuTACs) comprising proteasomal ubiquitin receptor ADRM1 (ARM1; hRpn13) linked to programmed cell death 1 ligand 1 (CD274; PD-L1) and/or bromodomain-containing protein 4 (BRD4; HUNK1)-targeting moiety. They are reported to be useful for the treatment of cancer, eye disorders, viral infections, autoimmune diseases, inflammatory disorders and systemic inflammatory response syndrome.

Humanwell Healthcare (Group) Co. Ltd. has divulged P2X purinoceptor 7 (P2RX7; P2X7) antagonists reported to be useful for the treatment of pain, inflammatory, neurological and immunological disorders.